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corresponding effect on microtubule stabilization. Our data 
suggest that ricolinostat in combination with bendamustine 
may be a novel combination with potential for use as an 
antitumor agent in lymphoma.
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Introduction
Many cellular functions, including cell cycle arrest and 
apoptosis, are regulated by histone and non-histone pro-
teins that are controlled by protein acetylation. The acetyla-
tion state of proteins is controlled by two opposing enzyme 
classes: histone acetyltransferases (HATs) and histone dea-
cetylases (HDACs) [1]. HDACs regulate gene expression 
and enzymatically remove the acetyl group from histones 
[2]. In some disease models including T–cell lymphoma 
(TCL) and Hodgkin lymphoma alterations were found in 
histone acetylation; this is correlated with an aggressive 
disease course and poor treatment outcomes [3, 4]. HDAC 
inhibitors (HDACi) are a novel class of drugs involved in 
the modification of epigenetic regulation that are being 
evaluated in clinical trials in hematological malignancies 
alone and in combination with approved drugs and with a 
good safety profile [5–7]. HDACi target tumor cells chang-
ing the acetylation of chromatin-associated histones [8], as 
well as a range of non-histone proteins, with diverse and 
important biological functions, including transcription fac-
tors involved in regulation of cell proliferation, migration 
and cell death [9, 10]. HDACi can either be pan inhibi-
tors that broadly target different HDAC enzymes, or selec-
tive inhibitors that target specific isozymes of HDAC [11]. 
The development of isozyme selective drugs may provide 
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with bendamustine in lymphoma cell lines. Cell viability 
was measured by MTT assay. Apoptosis, reactive oxygen 
species (ROS) generation, Bcl-2 protein expression, cell 
cycle progression and tubuline expression were determined 
by flow cytometry. The effects of ricolinostat alone and in 
combination on the caspases, PI3K/Akt, Bcl-2 pathways, 
ER stress and UPR were assessed by immunoblotting. 
Ricolinostat shows anti lymphoma activity when used as 
single agent and its capability to induce apoptosis is syn-
ergistically potentiated by the bendamustine in lymphoma 
cell lines. Drug combination reduced the proportion of 
cells in the  G0/G1 and S phases and caused an increase of 
“sub-G0/G1” peak. The synergistic effect accompanied with 
the increased ROS, activation of caspase-8, -9, and -3, the 
cleavage of PARP and modulated by Bcl-2 proteins fam-
ily. In addition, the exposure of ricolinostat induced the 
acetylation level of α-tubulin, the extend of which was not 
further modified by bendamustine. Finally, the apoptosis 
effect of ricolinostat/bendamustine may be mediated by a 
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a therapeutic benefit by minimizing toxicity. HDAC6 is 
responsible for tubulin deacetylation which plays a key 
regulatory role in the dynamic stability of the microtubules 
[12]. In hematological malignancies, HDAC6 has been 
reported to be overexpressed in primary and cultured multi-
ple myeloma cells and T-cell lymphoma [13, 14].
Ricolinostat (ACY-1215) inhibits HDAC6, resulting in 
tubulin hyperacetylation [15] and interacts synergistically 
in combination with bortezomib and carfilzomib to treat 
lymphoma and multiple myeloma (MM) cells [16–18]. 
Preclinical studies also confirmed the synergistic effects 
of HDACi in combination with conventional alkylating 
agents [19]. It may be a strategy to use an HDAC6 inhibitor 
in combination with a broad-spectrum chemotherapeutic 
agent in the clinic to reduce the possibility of developing 
resistance. A recent study showed that HDACi synergisti-
cally enhanced the anticancer effect of bendamustine in 
multiple myeloma cells [20]. Bendamustine is a bifunc-
tional compound which possess the activity of alkylating 
and purine analogue agents and demonstrated important 
results with a good toxicity profile in the therapy of indo-
lent lymphomas, chronic lymphocytic leukemia (CLL), 
MM, and mantle cell lymphomas (MCL) [21–23]. Benda-
mustine activates apoptosis pathways causing mitotic catas-
trophe [24].
The aim of this in  vitro study was to investigate the 
activity of ricolinostat alone and in combination with ben-
damustine to affect cell viability and apoptotic pathways 
in a panel of non-Hodgkin’s lymphoma (NHL) cell lines. 
Our results suggest that combination treatment produced a 
strong cytotoxic effect when incubated with lymphoma cell 
lines at concentrations that do not affect normal cell viabil-
ity. Demonstration of such cytotoxic effects coupled with 
the improved safety profile of a selective HDAC6 inhibitor 
[25], provide the rationale for the development of this com-
bination in the treatment of patients with lymphoma.
Materials and methods
Reagents and cells culture
Ricolinostat (ACY-1215) and ACY-241 were kindly pro-
vided by Acetylon Pharmaceuticals (Boston, USA). ACY-
241 is structurally related to ACY-1215 and selectively 
inhibits HDAC6 with similar biological effects.
Bendamustine was purchased from Selleck Chemicals. 
Reagents were dissolved in DMSO (Sigma Aldrich), and 
stored at −20 °C until use. In all experiments, the final con-
centration of DMSO which was used as vehicle control did 
not exceed 0.01%. Ricolinostat was investigated using a 
panel of six NHL cell lines: WSU-NHL, RL (follicular lym-
phoma, FL), Granta-519, Jeko-1 (mantle cell lymphoma, 
MCL), Hut-78 (cutaneous T cell lymphoma, CTCL) and 
Karpas-299 (anaplastic large cell lymphoma, ALCL). 
WSU-NHL, RL, Granta-519, Jeko-1 and Karpas-299 were 
purchased from the German Collection of Microorganisms 
and Cell Cultures (DSMZ). Hut-78 was purchased from the 
European Collection of Cell Cultures (ECACC). With the 
exception of GRANTA-519, lymphoma cell lines were cul-
tured in RPMI-1640 supplemented with 10% fetal bovine 
serum (FBS), 2  mM glutamine, and 100  U/mL penicillin 
and streptomycin. For Granta-519 cells, DMEM was used 
in place of RPMI-1640. Cell lines used in this study were 
thawed from early passage stocks and were passaged for 
less than 6 months.
Bone marrow mesenchymal stromal cells (BM-MSCs) 
were generated as previously described [26]. Peripheral 
blood mononuclear cells (PBMCs) were obtained from 
two patients with FL, two patients with MCL, one patient 
with CTCL and from three healthy volunteers using the 
Ficoll–Hypaque technique. The protocol was approved by 
the local Institutional Review Board. Written informed 
consent was obtained before the collection of the samples. 
All reagents were purchased from Euroclone.
Viability assay and clonogenic formation
Cell viability was evaluated by MTT colorimetric assay 
(CellTiter non-radioactive cell proliferation assay, Pro-
mega Corporation, Madison, USA), following the manu-
facturer’s instructions. NHL cell lines were incubated in 
triplicate with increasing concentrations of ricolinostat 
(0.01–100  µM) and bendamustine (25–300  µM) as single 
agents for 24–72 h to identify the  IC50 values of each drug. 
For assessment of drug combination effect, serial dilutions 
of the two agents were assessed using concentrations lower 
than the  IC50. NHL cell lines were cultured with fixed 
doses of ricolinostat (2, 2.5, 4, 5, 8, 10 µM) and bendamus-
tine (10, 20, 25, 40, 50, 100 µM).
For clonogenic assays, NHL cell lines were first exposed 
to ricolinostat alone and in combination with bendamustine 
in liquid culture for 24–48 h, then collected and incubated 
in methylcellulose and maintained for 10 or 14 days. Grow-
ing colonies (>50 cells) were counted under a microscope.
Co-culture of lymphoma cell lines with BM-MSCs
BM-MSCs (5 × 104 cells/well) were seeded in triplicate 
onto 96-wells plates, and incubated for 48 h to reach con-
fluence. After 48  h, lymphoma cell lines were seeded at 
2 × 104 cells/well in the presence or absence of BM-MSCs. 
The next day, cells were treated with ricolinostat alone or in 
combination with bendamustine. Non-adherent cells were 
collected at 24 and 48 h after addition of the drugs, and cell 
viability was evaluated.
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Cell cycle distribution
Cell lines were cultured at 1 × 106 cells/well for 24–48  h 
with ricolinostat alone and in combination with bendamus-
tine. Cell cycle analysis was determined by flow cytometry 
as described previously [27].
Assessment of apoptosis
Apoptosis was quantified using the Annexin V-FITC and 
propidium iodide (PI) binding assay, following the manu-
facturer’s instructions (Miltenyi Biotec, Germany), and 
analyzed by flow cytometry (FACS Calibur, BD) and Cell 
Quest data analysis software. Apoptotic cells were desig-
nated as Annexin  V+/PI− and Annexin  V+/PI+, showing 
early and late apoptosis, respectively.
Analysis of Bcl-2 expression
After treatment, the cells were fixed and permeabilized 
using the BD Cytofix/Cytoperm Kit™ (BD Biosciences, 
San Jose, CA, USA) according to the manufacturer’s 
instructions. Cells were incubated with FITC-conjugated 
mouse anti-human Bcl-2 monoclonal antibody (BD Bio-
sciences, San Jose, CA, USA), or FITC-conjugated 
mouse IgG1 monoclonal isotype control antibody (BD 
Biosciences, San Jose, CA, USA), then analyzed by flow 
cytometry.
Assessment of reactive oxygen species generation
Cells treated for 24  h, were incubated with 5  µM of 
2′,7′-dichloroflourescein diacetate (DCFH-DA; Sigma-
Aldrich St. Louis, MO, USA) in PBS at 37 °C for 30 min. 
The free radical scavenger acetyl-l-cysteine (NAC) (Sigma-
Aldrich St. Louis, MO, USA) to assess the role of ROS 
generation in apoptosis. Cells were pre-incubated with 
12 mM NAC for 3 h followed by incubation with ricolin-
ostat and bendamustine either alone or in combination. 
 H2O2 was used as a positive control. The fluorescence 
intensity was read by flow cytometry on the FL1 channel 
within 45  min. ROS production was determined in gated 
live cells by comparing the intensity of fluorescence in 
treated versus untreated cells. The data were analyzed by 
Cell Quest data analysis software.
Western blot analysis
Cell pellets were resuspended in cold lysis buffer (Mamma-
lian Cell Extraction Kit; Biovision Inc. CA, USA) follow-
ing the manufacturer’s instructions. Cell lysates (50–100 μg 
of protein) were loaded onto pre-cast 4–20% (w/v) Mini-
protean TGX Precast Gels (Bio-Rad, USA), subjected to 
electrophoresis, and electrotransferred onto nitrocellulose 
membranes (Bio-Rad, USA). The membranes were incu-
bated overnight at 4 °C and were probed with antibod-
ies against the following protein: AKT, p-AKT (Ser473), 
GSK-3β, p-GSK-3β (Ser9), p70S6, p-p70S6 (Thr421/
Ser424), m-TOR, p-m-TOR (Ser2448), p90/RSK, p-p90/
RSK (Thr359/Ser363), 4EBP1, p-4EBP1 (Thr37/46), p21, 
p27, cyclin E, cyclin D, cyclin B, Bip, p-IRE1α, IRE1α, 
CHOP, p-PERK, PERK, ATF6 (Pierce), Thioredoxin 1 
(Tema Ricerca), Bax, Total Bad, p-Bad (Ser112), p-Bad 
(Ser136), Bim, BCL-xL, Mcl-1, HDAC6, acetyl-alpha 
tubulin, caspase 8, caspase 3 (Asp175), caspase 9 (Asp353) 
and PARP. Caspases and PARP expressions were evaluated 
also after 1  h of pretreatment with 40  µM of zVAD-fmk 
(Sigma), a broad caspase inhibitor. The majority of anti-
bodies were purchased from Cell Signaling Technology. 
For protein loading control, the blots were stripped and rep-
robed with anti-α-tubulin (Sigma) antibody to ensure equal 
protein loading. Images were acquired and analyzed using 
Image Lab Software v.3.0 (Chemidoc Imaging System, 
Bio-Rad).
Measurement of IL-10
After 24  h, the cell suspension was carefully centrifuged 
and cell culture supernatants collected for subsequent IL-10 
analysis. IL-10 expression was measured using a commer-
cially available IL-10 enzyme-linked immunosorbent assay 
(ELISA; R&D systems), according to the manufacturer’s 
instructions.
Analysis of tubulin expression
Cells were exposed to ricolinostat alone and in combination 
with bendamustine and, 24 h later, processed for the tubulin 
polymerization assay. Samples were prepared as described 
by Morrison KC et  al. [28]. For each sample, the mean 
fluorescence intensity was recorded using a FACS Calibur 
cytometer and analyzed using Cell Quest Software. Tubu-
lin levels were determined based on the geometric mean of 
the antibody/FITC fluorescence and were normalized to a 
value of 100 for the vehicle control. Paclitaxel and nocoda-
zole were used as positive and negative controls. Paclitaxel 
would induce the microtubule polymerization; in contrast, 
nocodazole induces depolymerization of microtubules. All 
reagents were purchased from Sigma Aldrich.
Statistical analysis, isobologram and combination index 
calculation
The effectiveness of the drugs and their combinations 
used in the present study were analysed using Calcusyn 
Software. The combination index (CI) and isobologram 
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plot were calculated according to the Chou–Talalay 
method [29]. Synergism, additivity, or antagonism were 
quantified by determining the combination index (CI) 
calculated by the Chou–Talalay equation. We assumed 
that CI < 1, CI = 1, and CI > 1 indicate synergistic, addi-
tive, and antagonistic effects, respectively. All in  vitro 
experiments were performed in triplicate, and repeated 
at least three times; a representative experiment was 
selected for the figures. Data are expressed as mean 
value ± standard error.
Statistical differences between controls and drug-
treated cells were determined by one-way analysis of 
variance (ANOVA). p values < 0.05 were considered sta-
tistically significant. Data were analysed using the Stata 
8.2/SE package (StataCorp LP).
Results
Ricolinostat has a cytotoxic effect in lymphoma cell 
lines
HDAC6 protein was expressed in all six NHL cell lines 
examined (Fig. 1a). The effect of ricolinostat on lymphoma 
cell viability was evaluated with escalating concentrations 
of ricolinostat (0.01–100  µM) for 24–72  h. Exposure to 
ricolinostat resulted in time and dose-dependent inhibi-
tion of cell viability with  IC50 values ranging from 1.51 to 
8.65  μM. Significant cytotoxic effect was observed after 
48  h of treatment in five out of six lymphoma cell lines 
present in the panel. The most sensitive cell lines were 
WSU-NHL and Hut-78  (IC50: 1.97–1.51 μM) and the less 
sensitive the MCL cell line Granta-519  (IC50: 20–64 µM) 
(Fig. 1b; Supplemental Table S1).
Fig. 1  a HDAC6 is expressed in six lymphoma cell lines. Whole-
cell lysates were subjected to western blotting using the indicated 
Abs. Tubulin was used to normalize protein loading. b Ricolinostat 
alone induced dose and time dependent manner growth inhibition in 
NHL cell lines that were treated with a serial dosage of ricolinostat 
(1–10  µM) for 24–72  h. Data shown are representative of at least 
three independent experiments and represent the mean ± SD. c Anti-
proliferative activity of bendamustine (25–300 µM) for 24 h. Values 
represent three independent experiments and represent the mean ± SD
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Growth inhibition of lymphoma cell lines 
by bendamustine alone
Bendamustine (25–300  μM) induced time and dose-
dependent inhibition of cell viability in lymphoma cell 
lines after 24–48  h with an  IC50 value after 24  h of 168, 
127 and 144 µM for WSU-NHL, Jeko-1 and Hut-78 cells, 
respectively (Fig. 1c). At 48 h, the  IC50 value ranged from 
83 to 106 µM for the same cell lines (data not shown).
Drug combination inhibited cell viability 
in a synergistic manner
The sensitive lymphoma cell lines of the panel (WSU-
NHL, Hut-78 and Jeko-1) were treated with increasing 
concentrations of ricolinostat (2, 2.5, 4, 5, 8 and 10  μM) 
in combination with bendamustine (10, 20, 25, 40, 50 
and 100 μM) and cell viability was assayed by MTT. The 
combination studies were performed at 24  h before the 
start of extensive apoptosis. Even if each drug alone was 
able to affect the cell viability in a dose dependent man-
ner, the combination drug treatment caused much stronger 
cytotoxic effect in all cell lines tested. Analysis using the 
Chou–Talalay method indicated that the effect of the com-
bination was synergistic in all the tested concentrations. A 
clear synergistic interaction was observed using concentra-
tions lower than the  IC50 after 24 h of treatment. After 24 h, 
ricolinostat (2, 4 and 8 μM) and bendamustine (10, 20 and 
40  μM) showed a synergistic interaction with a combina-
tion index (CI) raging between 0.027 and 0.553 in WSU-
NHL and Hut-78 cells, respectively (Fig. 2a; Table 1). The 
combination of ricolinostat (5, 10 μM) with bendamustine 
(50, 100 μM) showed a CI of 0.02 and 0.04 in Jeko-1 cells 
(Fig.  2a; Table  1). Combination treatment also decreased 
the percentage of viable PBMCs from patients with lym-
phoma but had minimal or no cytotoxic effect on PBMCs 
from healthy donors (Fig. 2a). Separate study of sequential 
treatment with ricolinostat before or after bendamustine 
enhanced cytotoxicity but was less synergistic than simul-
taneous treatment (data not shown). Based on the results 
of the combination in each cell line, we tested the dose of 
4 µM of ricolinostat and 20 µM of bendamustine for WSU-
NHL and Hut-78 cells and the dose of 5 µM of ricolinostat 
and 50 µM bendamustine for Jeko-1 cells. At these doses, 
which are lower than the  IC50, we reached the CI < 1.
Drug combination affects clonogenic survival of NHL 
cells and overcomes the protective effect of BM-MSCs
We studied the effect of the drug combination on self-
renewal by examining clonogenic growth in methylcel-
lulose. Colony formation reflected clonogenic potential 
at the end of the treatment period in liquid culture (24 h). 
Clonogenic assay revealed that the drug combination inhib-
ited colony formation significantly compared with the 
drugs alone (Fig. 2b). We next examined whether ricolin-
ostat/bendamustine inhibited cell viability even in the 
presence of BM-MSCs. WSU-NHL and Hut-78 cell lines 
were co-cultured with BM-MSCs and treated with 4 µM of 
ricolinostat and/or 20  µM of bendamustine, while Jeko-1 
was treated with 5 µM of ricolinostat and 50 µM of ben-
damustine and cell viability was assessed by MTT. Drug 
combination decreased cell viability of lymphoma cell lines 
co-cultured with BM-MSCs, indicating that it overcomes 
the protective effects conferred by the bone marrow micro-
environment and the combination had minimal or no cyto-
toxic effect on BMSCs (Fig. 2c).
Ricolinostat/bendamustine affected the cell cycle 
through the regulatory proteins p21 and p27
Ricolinostat alone induced an increase of the percentage of 
cells in the  G0/G1 phase compared with untreated control, 
while the drug combination reduced the proportion of cells 
in the  G0/G1 and S phases and caused an increase of “sub-
G0/G1” peak (Fig. 3a, b). To further characterize the cell-
cycle regulatory effects of ricolinostat alone and in com-
bination, we analyzed the levels of cell-cycle regulatory 
proteins, including cyclin D1, cyclin E, p21, p27, which 
control  G1/S transition. The treatment with drug combina-
tion for 24 h caused a decrease of cyclin D1, and cyclin E 
in lymphoma cells, in parallel the level of p21 protein and 
p27 increased (Fig. 3c).
Apoptosis induced by drug combination is mediated 
by Bcl-2 family proteins and caspase activation
Ricolinostat alone induced apoptosis in all cell lines exam-
ined in a time and dose dependent manner (Fig. 4a). This 
effect was enhanced by adding bendamustine to ricolin-
ostat. After 24 h, ricolinostat/bendamustine induced signifi-
cantly greater apoptosis compared with either drug alone 
(Fig. 4b, c). Combination treatment at 48 h was too toxic 
to be assessed (data not shown). Since the involvement of 
Bcl-2 family proteins in DNA damage-induced apoptosis 
is well-known, we examined the expression of Bcl-2 fam-
ily members including anti-apoptotic proteins and pro-
apoptotic proteins. In comparison to the effects of the sin-
gle treatments, the drug combination reduced the protein 
level of Bcl-2 (Fig.  5a), Bcl-xL and Mcl-1 (Fig.  5b) and 
increased the levels of the pro-apoptotic members of Bcl-2 
family, such as Bax, Bim, Noxa, p-Bad112 and p-Bad136 
(Fig.  5b). Ricolinostat alone and in combination induced 
PARP cleavage, the hallmark of apoptosis and activation of 
caspase-8, -9 and -3 in all three cell lines (Fig. 5c). With 
the presence of ZVAD, a pan caspase inhibitor, the effect 
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of the drug combination on caspases and PARP cleavage 
was completely inhibited, indicating that drug combina-
tion induced apoptosis by activating the caspase pathway 
(Fig. 5c).
Drug combination activated ER stress through ROS 
generation
Since ROS generation is implicated in HDACi mediated 
cell death [30], we investigated whether ROS might be 
involved in the synergism between ricolinostat and benda-
mustine. In WSU-NHL, Hut-78 and Jeko-1, the exposure to 
ricolinostat alone (1, 5 and 10 µM) resulted in an increase 
of ROS production: from 10.8 to 27% at 24 h with a fur-
ther increase at 48 h (from 15 to 36.6%). Ricolinostat/ben-
damustine in combination induced a significant increase in 
ROS-positive cells from 54 to 71% in the three cell lines, 
with fold increase ranging from 2.2 to 3.6 when compared 
with each drug alone, and co-administration of the anti-
oxidant NAC, a ROS scavenger, reduced the generation 
of ROS (Fig. 6a, b). ROS generation induced by the drug 
combination were linked to a decrease of thioredoxin-1 
(Trx1) expression (Fig. 6c). The Trx system is an antioxi-
dant system integral to maintaining the intracellular redox 
state. Trx can also scavenge ROS and directly inhibits pro-
apoptotic proteins. The ROS generation and Trx1 inhibition 
Fig. 2  a Synergistic effect of drug combination on cell viability of 
WSU-NHL, Hut-78, Jeko-1, cell lines and PBMCs isolated from two 
FL patients (Pt#1, Pt#2), two MCL patients (Pt#3 and Pt#4), one 
CTCL patient and three healthy subjects. The synergistic effect is 
confirmed with the isobologram analysis (interaction index <1). Data 
are expressed as a percentage of untreated control cells and represent 
the mean ± SD of triplicate culture. b Effects of drug combination 
on clonogenic survival. WSU-NHL, Hut-78 and Jeko-1 cells were 
treated with ricolinostat (R) and bendamustine (B), at the indicated 
doses, in liquid culture for 24  h. After treatment, cells were incu-
bated in methylcellulose and colonies consisting of more 50 cell were 
counted after 10 days. The relative percentage with respect to control 
cells are shown and represent the mean ± SD of three separate experi-
ments (*p < 0.001 vs R and B). c Cell viability of WSU-NHL, Hut-78 
and Jeko-1 cells co-cultured with or without BM-MSCs and exposed 
to drugs alone and in combination, at the indicate doses, for 24 h. All 
data are expressed as a percentage of untreated control ± S.D of tripli-
cate culture (*p < 0.001 vs R and B)
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play an important role in the toxicity of combined treat-
ment in lymphoma cell lines. ROS generation is frequently 
associated with the activation of transcription factors linked 
with induction of endoplasmic reticulum (ER) stress and 
this could play a crucial role in apoptosis induced by the 
drug combination. The accumulation of misfolded proteins 
in the endoplasmic reticulum causes ER stress and causes 
the unfolded protein response (UPR) [31]. To evaluate the 
possible involvement of the ER stress response in apopto-
sis induced by the drug combination, we analyzed by west-
ern blot the possible modification of the protein expres-
sion levels of some hallmarks of ER stress such as IRE1-α, 
ATF6 and PERK and the expression of UPR sensors such 
as BIP and CHOP. The apoptosis induced by combina-
tion treatment correlated with increased expression of 
IRE1-α, PERK and ATF6, which are three ER stress sen-
sors (Fig. 6d).The UPR stress proteins BiP and CHOP were 
clearly induced by ricolinostat, and the effect was main-
tained in the combination with bendamustine.
Co-exposure to ricolinostat/bendamustine leads to AKT 
pathway inactivation
AKT pathway is the most important and intensively inves-
tigated signaling pathway that plays central roles in gov-
erning the cell survival and its dysregulation is related to 
the development of many diseases. To evaluate the effects 
of ricolinostat/bendamustine on AKT pathway signaling, 
we analyzed the phosphorylation status of Akt and some 
downstream targets including GSK3β, mTOR, 4EBP1, 
p90RSK and p70S6kinase. Combined treatment induced 
down-regulation of p-AKT and multiple downstream tar-
gets (Fig. 7a).
Effect of ricolinostat alone and in combination 
on the acetylation of α-tubulin
Studies showed that ricolinostat increased the acetylation 
of α-tubulin, a specific substrate of HDAC6 [15]. Using 
antibodies specifically recognizing acetylated α-tubulin, 
western blot analysis revealed that exposure of ricolinostat 
induced the acetylation of α-tubulin in lymphoma cells, the 
extent of which was not further modified by bendamustine 
(Fig. 7b).
Ricolinostat alone and in combination stabilizes 
microtubules
α-tubulin is a non-histone substrate for HDAC6 enzymes 
[32] and its overexpression promotes chemotactic cell 
movement, a function related to the microtubules. The 
accumulation of acetylated α-tubulin is associated with 
stabilized microtubule structures, which disrupt the align-
ment of chromosomes during mitosis and lead to apopto-
sis. Tubulin deacetylation is associated with microtubule 
depolymerization, and accumulation of acetylated tubu-
lin following treatment with HDAC6 inhibitors would be 
expected to lead to microtubule stabilization [28]. To elu-
cidate the effect of ricolinostat alone and in combination 
with bendamustine on tubulin polymerization, we utilized a 
cytometric based technique [28] that allows direct quantita-
tive evaluation of tubulin without interference from micro-
tubule-associated proteins or other complicating factors 
thus enabling facile comparison of compounds that affect 
tubulin polymerization.
Lymphoma cell lines were treated for 24 h with ricolin-
ostat alone and in combination with bendamustine with 
either the microtubule destabilizer nocodazole (1  μM) 
or the microtubule stabilizer paclitaxel (100  nM). This 
was followed by whole cell-based quantitative measure-
ment of tubulin polymerization using α-tubulin staining. 
Ricolinostat in combination with bendamustine induced 
an increase of intensity of fluorescence and acted as a 
microtubule stabilizer, with an effect similar to paclitaxel 
Fig.  7c. Nocodazole had the opposite effect, as treatment 
with this tubulin destabilizer clearly decreased tubulin 
polymerization.
Ricolinostat alone and in combination down-modulated 
IL 10 expression
HDAC6 has been shown to be involved in regulation of 
inflammatory and immune responses [33]. IL-10 is a 
Table 1  Analysis of drug combination effects
Lymphoma cell lines were cultured with fixed doses of ricolinostat 
and bendamustine alone and in combination. Synergism, additivity, or 
antagonism were quantified by determining the CI calculated by the 
Chou–Talalay equation. Combination index (CI): CI < 1, synergism; 





Effect CI (CI 95%)
WSU-NHL
 2 10 0.75 0.553 (0.307–0.996)
 4 20 0.34 0.324 (0.116–0.900)
 8 40 0.17 0.305 (0.091–1.46)
Hut-78
 2 10 0.70 0.374 (0.313–0.446)
 4 20 0.44 0.124 (0.079–0.193)
 8 40 0.13 0.027 (0.011–0.067)
Jeko-1
 2.5 25 59.6 1.13 (0.77–1.67)
 5 50 13.3 0.04 (0.01–0.15)
 10 100 13.7 0.02 (0.01–0.31)
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multifunctional cytokine produced by diverse immune 
cell types, including B cells and subsets of T cells. IL-10 
has a potent stimulating effect, inducing proliferation and 
differentiation [34]. Therefore, we studied the expression of 
IL-10 in lymphoma cell lines after treatment with ricolin-
ostat alone and in combination. Ricolinostat alone induced 
Fig. 3  a Representative cell cycle profile of WSU-NHL, Hut-78 
and Jeko-1 treated at the indicated doses for 24 h. The bars of M1, 
M2, M3 and M4 indicate the sub-G0/G1,  G0/G1, S and  G2/M phases, 
respectively. b cell cycle distribution (%) of lymphoma cell lines 
in different phases after 24  h of treatment. Values represent the 
mean ± SD of three independent experiments. c WSU-NHL, Hut-78 
and Jeko-1 treated with the drugs alone or in combination for 24 h. 
Whole-cell lysates were subjected to Western blotting using the indi-
cated Abs. Tubulin was used to normalize protein loading
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a significant down-regulation of IL-10, that was especially 
evident in WSU-NHL with a fold decrease of 6.6 compared 
to control. The drug combination affected the IL-10 pro-
duction in all the three cell lines with a fold decrease of 
5.77 in WSU-NL; 11.5 in Hut-78; 10.9 in Jeko-1 cells com-
pared with ricolinostat alone (Fig. 7d).
Discussion
HDACi have emerged as a new class of target therapy and 
have showed synergy with a number of anticancer drugs. 
HDACi are known for their selective cytotoxicity that dis-
criminates between normal and tumor cells. Selective inhi-
bition may improve the efficacy and reduce the toxicity 
of pan-HDAC inhibitors observed in the clinic. HDAC6, 
a class IIb HDAC, is a key regulator of many signaling 
pathways that are associated to cancer, thereby making 
HDAC6 an attractive target. Ricolinostat is a selective 
HDAC6 inhibitor, which induces synergistic cell cytotoxic-
ity in combination with proteasome inhibitors [15–17] and 
immunomodulatory agents [35, 36] in MM cell lines and 
animal models. Ricolinostat has demonstrated an excellent 
safety and tolerability profile in Phase I trials as a single 
agent and in drug combinations [36]. Although the antitu-
mor activity of HDACi was confirmed in various studies, it 
is widely accepted that HDACi in combination with other 
antitumor drugs may be more effective than HDACi alone. 
The combination of two compounds with different mecha-
nism of action can lead to a potential synergistic effect and 
improved pharmacological potency. Preclinical and Phase 
 1a clinical data [25] support the hypothesis that the safety 
profile of a selective HDACi will facilitate combination 
treatment with other active agents such as bendamustine, 
which has being given new perspective in treating hemato-
logic malignancies such as CLL, lymphoma and MM [37, 
Fig. 4  a Representative dot blot of WSU-NHL cells treated with 
ricolinostat alone (1, 2, 5, 10 µM) for 24 h and assayed for apoptosis 
by annexin V/PI staining (left panel); Percentages of apoptotic cells 
of WSU-NHL, Hut-78 and Jeko-1 cell lines after 24–48 h of exposure 
to ricolinostat alone (panel right). Values represent the mean ± SD of 
three independent experiments. b Representative dot blot of WSU-
NHL, Hut-78 cells treated with 4 µM of ricolinostat in combination 
with 20 µM of bendamustine for 24 h and Jeko-1 cells treated with 
combination of 5 µM ricolinostat and 50 µM bendamustine. The flow 
cytometry shows an increase of apoptosis induced by combination. c, 
Percentages of apoptotic cells (early and late apoptosis) treated with 
ricolinostat (R) and bendamustine (B) as above (*p < 0.001 vs Ctrl; 
**p = 0.003 vs Ctrl)
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38]. Bendamustine is known to cause intra- and inter-strand 
DNA cross-links that initiate a DNA damage response [24]. 
Repair of this damage leads to survival of cells; therefore, 
a strategy to overcome this survival mechanism may be 
the combination of bendamustine with a drug involved in 
the modification of epigenetic regulation. We present data 
indicating that ricolinostat shows anti lymphoma activity 
as single agent and its ability to induce apoptosis is syn-
ergistically increased by bendamustine in lymphoma cell 
lines. Six cell lines of different histology have been tested. 
Ricolinostat enhanced bendamustine induced inhibition of 
cell viability, reduced clonogenic survival and overcame 
the proliferative advantage of BMSCs with minor toxic-
ity against PBMCs. Drug combination reduced the pro-
portion of cells in the  G0/G1 and S phases and caused an 
increase of “sub-G0/G1” peak, modulated Bcl-2 protein 
family members and activated caspase-3 leading to PARP 
degradation. Caspase activation occurs through various 
pathways, such as mitochondria, death receptor and ER 
pathway. HDACi are known to activate caspases by mito-
chondrial or death receptor-mediated pathways [39]. There 
are different studies showing that HDACi induce ROS 
production and caspase activation [30] including ricolin-
ostat [15]. ROS production, induced by HDACi, leads 
to activation of caspase and generates apoptosis in vari-
ous types of cancer cells through an extrinsic or intrinsic 
pathway [30]. In most cell types the main source of ROS 
are the mitochondria and anomalies in ROS generation 
may play an important role in signaling mechanisms of 
apoptosis. Irregular ROS production can also promote the 
conformational changes of members of the pro-apoptotic 
Bcl-2 family and their intervention in increasing the per-
meability of the mitochondrial membrane. Ricolinostat/
bendamustine induced apoptosis via ROS generation and 
Fig. 5  a Bar graph shows the representative data (%) of Bcl-2 levels 
in WSU-NHL, Hut-78 and Jeko-1 cells, evaluated by flow cytometry 
(*p = 0.001; **p = 0.009; ***p = 0.002). b Drug combination medi-
ated the down regulation of anti-apoptotic proteins and phosphoryla-
tion of the pro-apoptotic proteins. Whole-cell lysates were subjected 
to western blotting using the indicated Abs. Tubulin was used to nor-
malize protein loading. c Representative western blot for caspases-8, 
-9, -3 and PARP with or without ZVAD in cellular extracts from 
WSU-NHL, Hut-78 and Jeko-1 cells. Tubulin is shown as a loading 
control
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apoptosis was attenuated by pre-incubation with NAC, 
suggesting that ROS production is likely involved in the 
mode of action of this drug combination in lymphoma cell 
lines. ROS production induced by the drug combination 
was associated with decreased expression of Trx, a ubiq-
uitous protein with pleiotropic effects that functions as an 
intracellular antioxidant. Trx stimulates tumor growth and 
inhibits both spontaneous and drug-induced apoptosis [40]. 
Studies have shown that this antioxidant is upregulated in 
certain types of tumors [41, 42] possibly giving tumor cells 
a survival advantage in order to survive to elevated oxida-
tive stress. The overexpression of Trx is associated with 
resistance to many anticancer drugs and the inhibition of 
Trx expression may overcome drug resistance and prob-
ably sensitize lymphoma cells to other chemotherapeutic 
agents. Thus, decreasing Trx levels may contribute in the 
treatment of lymphoma. The mechanism involved in the 
HDACi induced cell death is still unclear, although, oxi-
dative stress has been identified as a mechanism involved 
in the cytotoxicity of HDACi but the manner by which 
HDACi induce oxidative stress is poorly understood. Our 
results suggest an association between cytotoxicity of the 
drug combination and ER-stress loading. The expression 
of ER-stress related proteins demonstrated that treatment 
Fig. 6  a Representative histograms showing ROS level from WSU-
NHL after treatment with drugs alone and in combination for 24. 
The bar M2 indicates the fraction of ROS positive cells. b Percent-
age of cells with increased ROS level from drug combination com-
pared with the control cells. The co-administration of the antioxidant 
NAC blocked the increased of ROS generation.  H2O2 was used as a 
positive control. Data are expressed as the mean ± SD of triplicate 
culture. (*p < 0.001 vs ricolinostat and bendamustine). c Western blot 
of cellular extracts from WSU-NHL, Hut-78 and Jeko-1 cells probed 
with antibody against Trx-1. Tubulin was used to normalize protein 
loading. d Drug combination mediated ER stress and UPR signaling. 
Representative western blots of cellular extracts from WSU-NHL, 
Hut-78 and Jeko-1 treated with the drugs alone or in combination 
at the indicated doses for 24 h. Whole-cell lysates were subjected to 
western blotting using the indicated Abs. Tubulin was used to nor-
malize protein loading
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with ricolinostat plus bendamustine was a potent combina-
tion for ER-stress loading, compared with each drug alone. 
Bip, which plays a central regulatory role in the unfolded 
protein response (UPR), represents a protein recently 
identified, which acetylation is induced by HDAC inhibi-
tion, leading to UPR activation. HDAC6, which primar-
ily resides in the cytoplasm, has also been implicated as 
the primary enzyme contributing to the acetylation of the 
ER-localized chaperone protein Bip [43]. Specifically, the 
UPR is a dynamic response to ER stress that may initially 
serve a protective function but which may ultimately pro-
mote cell death [44]. Activated BiP binds the accumulated 
unfolded proteins and dissociates from ER stress sensors 
PERK, ATF6, and Ire-1α, inducing ER stress [31]. Histone 
acetylation is known to result in the opening of condensed 
chromatin, which is in turn associated with transcriptional 
activation. A variety of non-histone proteins are subject to 
acetylation and deacetylation modifications. One non his-
tone target for HDAC6 is tubulin [45]. It has been docu-
mented that disturbances in either microtubule assembly or 
disassembly have destructive effects on cellular functions, 
ultimately leading to cell death. Our data showed that the 
drug combination has effects on tubulin acetylation and cell 
apoptosis. We observed an increase in tubulin acetylation, 
suggesting that the anticancer activity of ricolinostat/ben-
damustine may be attributed in part to effects on microtu-
bule stabilization. Acetylation of α-tubulin was not further 
modified by bendamustine. Nocodazole interferes with the 
dynamic assembly of microtubule by preventing tubulin 
polymerization [46]. In contrast, paclitaxel exerts its anti-
cancer effect partly by blocking tubulin depolymerization 
and consequently stabilizing microtubule [47]. The inhibi-
tion of HDAC6 function leads to acetylation of tubulin and 
microtubules and thus stabilizes microtubule [48]. The fact 
Fig. 7  a, b Western blots of cellular extracts from WSU-NHL, Hut-
78 and Jeko-1 treated with the drugs alone or in combination at the 
indicated doses for 24 h. Whole-cell lysates were subjected to western 
blotting using the indicated Abs. Tubulin was used to normalize pro-
tein loading. c Representative data from analyses of tubulin polym-
erization assessed by anti-α-tubulin staining and flow cytometry. 
WSU-NHL, Hut-78 and Jeko-1 treated with ricolinostat alone and in 
combination at the indicated doses as above for 24 h as well as with 
the microtubule destabilizer nocodazole (1 μM) and the microtubule 
stabilizer paclitaxel (100 nM). Data are expressed as mean ± SD and 
were obtained from three independent experiments performed in trip-
licate (*p < 0.001 vs R and B alone). d Effect of drug combination 
on IL-10 secretion in WSU-NHL, Hut-78 and Jeko-1 cells treated 
as above. IL-10 secretion was analyzed by ELISA. Data are means 
(±SD) of at least three separate experiments each performed in dupli-
cate (*p < 0.001 vs R and B)
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that these agents interrupt the microtubule dynamics sup-
ports the rationale for a combination of these anticancer 
agents, a strategy that has been explored in preclinical and 
clinical studies. In conclusion, several studies have dem-
onstrated that HDACi induce oxidative stress in different 
types of cancer cells and thus can be used as a strategy to 
treat cancer. Understanding how HDACi can alter the redox 
status in cancer cells is of critical importance for their 
development and better design of clinical trials that include 
combination of HDACi with other anticancer agents. The 
basis for combination therapy is to combine drugs acting 
on different mechanisms, thereby potentiating efficacy and 
decreasing drug resistance that cancer cells may develop.
Our study demonstrated that the HDAC6 inhibitor 
ricolinostat is effective in reducing lymphoma cell growth 
and increasing apoptosis as a single agent and the efficacy is 
increased by the combination with bendamustine. Ricolin-
ostat synergistically enhances bendamustine-induced 
growth inhibition in lymphoma cells mainly through mul-
tiple mechanisms, including ROS generation, ER stress, 
acetylation of tubulin and induction of apoptosis. These 
preclinical studies suggest that bendamustine in combina-
tion with epigenetic therapy, such as ricolinostat, may be 
promising treatment regime for managing lymphoma.
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